Compounded and Counterfeit Semaglutide: What the FDA Is Warning About
Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Search
8 stories for“compounded semaglutide”
Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024

Novo Nordisk folded Rybelsus into the Ozempic name in May and put a self-pay price on it. Getting a peptide to survive the stomach is a real achievement, but the tablet is not simply the injection in another form.
Aug 11, 2026

Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024

Insulin is a peptide. So is Ozempic. So is the unlabelled vial someone is selling on Telegram. The word describes a chemical class, not a level of evidence, and that gap is where the market lives.
Aug 11, 2026

Berberine lowers cholesterol and blood sugar in small trials, but comparing it to semaglutide misreads both the data and the biology.
Feb 14, 2024

On 23 and 24 July, an FDA advisory committee looked at seven peptides and recommended that pharmacies be allowed to compound several of them. The vote is not binding, and the evidence gap has not moved.
Aug 11, 2026

Research use only is a legal phrase, not a quality standard. Testing of peptides bought online keeps finding the wrong dose, the wrong compound, or contamination in something people inject at home.
Aug 12, 2026

Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
